TAC-302 / Otsuka, Meiji Seika, Taiho - LARVOL DELTA

Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. (clinicaltrials.gov) - P2 | N=195 | Completed | Sponsor: Taiho Pharmaceutical Co., Ltd. | N=76 ➔ 195

Enrollment change • Overactive Bladder • Urology

Is It Possible to Regenerate the Underactive Detrusor? Part 1 Molecular and Stem Cell Therapies Targeting the Urinary Bladder and Neural Axis ICI-RS 2024. (PubMed, Neurourol Urodyn) - "Several options are currently being pursued in the search for an elusive molecular or stem cell option for enhancing the power of the detrusor muscle. These encompass a wide range of approaches that target each aspect of the contraction mechanism including the urothelium of bladder and urethra, myocyte, and neural pathways. While none of these have shown unequivocal clinical utility, some appear promising. Lessons from other fields of medicine might prove instructive."

Journal • Review • Urology • GRP-10

Efficacy of TAC-302 for patients with detrusor underactivity and overactive bladder: a randomized, double-blind, placebo-controlled phase 2 study. (PubMed, World J Urol) - P2 | "Considering the significant effects on BCI in males and BVE in both sexes, TAC-302 may benefit patients with DU."

Clinical • Journal • P2 data • Overactive Bladder • Urology